Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin and Gemcitabine in Metastatic Breast Cancer
NCT00027989Phase 2Unknown
- Sponsor
- Pharmatech Oncology
- Start
- Dec 2001
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and gemcitabine in breast cancer, sponsored by Pharmatech Oncology. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
pegylated liposomal doxorubicingemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00027989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027989.